RT Journal Article SR Electronic T1 Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.11.10.20228361 DO 10.1101/2020.11.10.20228361 A1 Meoni, Gaia A1 Ghini, Veronica A1 Maggi, Laura A1 Vignoli, Alessia A1 Mazzoni, Alessio A1 Salvati, Lorenzo A1 Capone, Manuela A1 Vanni, Anna A1 Tenori, Leonardo A1 Fontanari, Paolo A1 Lavorini, Federico A1 Peris, Adriano A1 Bartoloni, Alessandro A1 Liotta, Francesco A1 Cosmi, Lorenzo A1 Luchinat, Claudio A1 Annunziato, Francesco A1 Turano, Paola YR 2020 UL http://medrxiv.org/content/early/2020/11/13/2020.11.10.20228361.abstract AB The current pandemic emergence of novel coronavirus disease (COVID-19) poses a relevant threat to global health. SARS-CoV-2 infection is characterized by a wide range of clinical manifestations, ranging from absence of symptoms to severe forms that need intensive care treatment. Here, plasma-EDTA samples of 30 patients compared with age- and sex-matched controls were analyzed via untargeted nuclear magnetic resonance (NMR)-based metabolomics and lipidomics. With the same approach, the effect of tocilizumab administration was evaluated in a subset of patients. Despite the heterogeneity of the clinical symptoms, COVID-19 patients are characterized by common plasma metabolomic and lipidomic signatures (91.7% and 87.5% accuracy, respectively, when compared to controls). Tocilizumab treatment resulted in at least partial reversion of the metabolic alterations due to SARS-CoV-2 infection. In conclusion, NMR-based metabolomic and lipidomic profiling provides novel insights into the pathophysiological mechanism of human response to SARS-CoV-2 infection and to monitor treatment outcomes.Author summary The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is markedly affecting the world population. Here we report about the small-molecule profile of patients hospitalized during the first wave of the COVID-19 pandemic. Using magnetic resonance spectroscopy, we showed that the infection induces profound changes in the metabolome. The analysis of the specific metabolite changes and correlations with clinical data enabled the identification of potential biochemical determinants of the disease fingerprint. We also followed how metabolic alterations revert towards those of the control group upon treatment with tocilizumab, a recombinant humanised monoclonal antibody against the interleukin-6 receptor. These results open up possibilities for the monitoring of novel patients and their individual response to treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementUnfunded studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Comitato Etico Regionale-sezione area vasta centro (protocol 16859) and it complies with the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from recruited patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the NMR files will be available from the MetaboLights database after publication.